Interleukin-17 in inflammatory myopathies.

Current Rheumatology Reports
Anne Tournadre, Pierre Miossec

Abstract

Since the identification of interleukin (IL)-17 as a T-cell-derived cytokine 15 years ago, the contribution of the T-helper type 17 (Th17) pathway in inducing and maintaining chronic inflammation has been well-established, particularly in rheumatoid arthritis. In addition to the main Th1 profile first suggested to contribute to inflammatory myopathies, the presence in inflamed muscle tissue of myositis of IL-17-producing cells, in association with activated dendritic cells, suggests a local activation of the IL-23-Th17 pathway. IL-17 can act on muscle cells together with proinflammatory cytokines produced by monocytes and innate immunity to amplify the immune response that could lead to muscle destruction. Evidence for activation of the Th17 pathway in myositis lesions and in vitro effects of IL-17 on muscle cells suggest IL-17 as a therapeutic target. Inhibitors of IL-17 have been tested in other inflammatory conditions, but the position of IL-17 inhibition in the treatment of inflammatory myopathies remains to be defined.

References

Oct 1, 1992·Journal of the Neurological Sciences·L AustinN Vakakis
Nov 8, 2001·Current Opinion in Rheumatology·Y P Li, M B Reid
Aug 11, 2007·Current Rheumatology Reports·Anne Tournadre, Pierre Miossec
Dec 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Saloua ZrioualPierre Miossec
Feb 24, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Saloua ZrioualPierre Miossec
Aug 28, 2009·The New England Journal of Medicine·Pierre MiossecVijay K Kuchroo
Oct 12, 2010·Science Translational Medicine·Wolfgang HueberFranco Di Padova

❮ Previous
Next ❯

Citations

Oct 12, 2012·Endocrine·Tiziana MontalciniArturo Pujia
Sep 27, 2003·Lancet·Marinos C Dalakas, Reinhard Hohlfeld
Aug 14, 2015·International Journal of Molecular Sciences·Boel De Paepe, Jana Zschüntzsch
Apr 18, 2013·The Journal of Surgical Research·Shinji FuruyaHideki Fujii
Oct 11, 2015·Bone·Priya Londhe, Denis C Guttridge
Oct 3, 2014·Clinical Reviews in Allergy & Immunology·Britt NakkenPeter Szodoray
Aug 25, 2015·Mediators of Inflammation·György NagyPeter Szodoray
Oct 24, 2013·Expert Opinion on Therapeutic Targets·Jun-Wei YanJing Wang
Nov 8, 2014·Scandinavian Journal of Rheumatology·A NotarnicolaF Iannone
Jul 5, 2015·The Journal of Surgical Research·Shinji FuruyaHideki Fujii
Jun 8, 2014·Biochimica Et Biophysica Acta·Yue-Bei Luo, Frank L Mastaglia
Dec 4, 2019·The Journal of Clinical Investigation·Anthony J LentscherTerence S Dermody
Mar 11, 2020·Clinical Rheumatology·Gustavo Luiz Behrens PintoSamuel Katsuyuki Shinjo
Oct 27, 2018·Frontiers in Neurology·Boel De PaepeJan L De Bleecker
Oct 20, 2020·Frontiers in Physiology·Adriana C BonomoWilson Savino
Mar 4, 2021·Medicine·Rebecca De LorenzoPatrizia Rovere-Querini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.